Chronic potentiation of metabotropic glutamate receptor 2 with a nanobody accelerates amyloidogenesis in Alzheimer's disease.
Lafon, P.-A.; Tsitokana, M. E.; Alenda, U.; Philibert, C. E.; Oosterlaken, M.; Cimadevila, M.; Monnic, J.; Roux, S.; Bessie, J.; Diem, S.; Vandermoere, F.; Prezeau, L.; Chames, P.; Kniazeff, J.; Claeysen, S.; Pin, J.-P.; Perrier, V.; Liu, J.; Rondard, P.
Show abstract
Immunotherapy of Alzheimers disease (AD) is a promising approach to reduce the accumulation of amyloid-beta (A{beta}), a critical event in the onset of the disease. Targeting the group II metabotropic glutamate receptors, mGlu2 and mGlu3, could be important in controlling A{beta} production, although their respective contribution remains unclear due to the lack of selective tools. Here, we show that enhancing mGlu2 receptor activity increases A{beta}1-42 peptide production whereas activation of mGlu3 has no effect. We show that such a difference likely results from the direct interaction of APP with mGlu3, but not with mGlu2 receptors, that prevents APP amyloidogenic cleavage and A{beta}1-42 peptides production. We then show that chronic treatments of the AD model 5xFAD mice with a brain-penetrating mGlu2-potentiating nanobody accelerated amyloid aggregation and exacerbated memory deficits, but had no effect in control mice. Our results confirm that a selective mGluR2 activation exacerbates AD disease development, suggesting that therapeutic benefices could be obtained with blockers of this receptor. Our study also provides the proof-of-concept that chronic administration of nanobodies targeting neuroreceptors can be envisioned to treat brain diseases.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Glycated alpha-synuclein assemblies cause distinct Parkinsons disease pathogenesis in mice 94%
- Fast purification of recombinant monomeric amyloid-β from E. coli and amyloid-β-mCherry aggregates from mammalian cells 94%
- Exifone is a Potent HDAC1 Activator with Neuroprotective Activity in Human Neuronal Models of Neurodegeneration 94%
Similar papers in this journal
Similar papers in this journal
- Tau depletion in human neurons mitigates A beta-driven toxicity 95%
- Loss of function of the mitochondrial peptidase PITRM1 induces proteotoxic stress and Alzheimer's disease-like pathology in human cerebral organoids 95%
- Alzheimer's genetic risk factor FERMT2 (Kindlin-2) controls axonal growth and synaptic plasticity in an APP-dependent manner. 95%
Similar papers in this journal
- SKA2 regulated hyperactive secretory autophagy drives neuroinflammation-induced neurodegeneration 96%
- A nanobody-based fluorescent reporter reveals human α-synuclein in the cell cytosol 96%
- Endo-lysosomal Aβ concentration and pH enable formation of Aβ oligomers that potently induce Tau missorting 95%
Similar papers in this journal
- A peptide inhibitor of Tau-SH3 interactions ameliorates amyloid-β toxicity 95%
- Extracellular tau clearance is governed by its aggregation state and independent of microglial activation by LPS and IFN-γ 93%
- LRRK2 kinase inhibition protects against Parkinson's disease-associated environmental toxicants 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.